ReviewCritical care (London, England)2016
Is the glutamine story over?
Review in Critical care (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 38 citations in OpenAlex.
- Abnormal carnitine concentrations in critical illness associated with compromised outcome.Critical care (London, England) · 2026Trial
- Preoperative immunonutrition as a strategy for reducing oxidative stress and inflammation in pancreatic ductal adenocarcinoma.Frontiers in immunology · 2026Article
- Gastrointestinal axis in post-traumatic sepsis: from molecular mechanisms to translational perspectives.Frontiers in immunology · 2026Review
- Nutritional and metabolic modulation of inflammation in critically ill patients: a narrative review of rationale, evidence and grey areas.Annals of intensive care · 2024Review
- Engineering the Signal Resolution of a Paper-Based Cell-Free Glutamine Biosensor with Genetic Engineering, Metabolic Engineering, and Process Optimization.Sensors (Basel, Switzerland) · 2024Article
- Glutamine Supplementation as an Anticancer Strategy: A Potential Therapeutic Alternative to the Convention.Cancers · 2024Review
- A Narrative Review: Analysis of Supplemental Parenteral Nutrition in Adults at the End of Life.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Engineering At-Home Dilution and Filtration Methods to Enable Paper-Based Colorimetric Biosensing in Human Blood with Cell-Free Protein Synthesis.Biosensors · 2023Article
- Serum Levels of Acylcarnitines and Amino Acids Are Associated with Liberation from Organ Support in Patients with Septic Shock.Journal of clinical medicine · 2022Article
- Blood Levels of Glutamine and Nitrotyrosine in Patients with Chronic Viral Hepatitis.International journal of general medicine · 2021Article
- Review
- Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation.Nutrients · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glutamine has been launched as a conditionally indispensible amino acid for the critically ill. Supplementation has been recommended in guidelines from international societies. Although data have been presented pointing out that glutamine supplementation may not be for everybody, recommendations for treatments and design of study protocols have included all critically ill patients. Results from more recent studies and meta-analyses indicate that indiscriminate use of glutamine supplementation in critically ill patients may actually cause harm rather than beneficial effects. This viewpoint sorts out arguments of controversy in the glutamine story.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.